Sur Access Portfolio
Our projects
As market access continues to evolve, staying ahead requires a commitment to understanding key trends and regulatory shifts. Our portfolio is a reflection of this commitment. Here, you'll find examples of our work and the insights we've developed on topics ranging from Swiss drug pricing to navigating early access programs. We invite you to explore how our expertise can inform and strengthen your own market access strategy.
How are Generics & Biosimilars Priced in Switzerland?
Navigating the pricing of generic and biosimilar drugs in Switzerland is a crucial challenge for market access. Switzerland's system relies on mandatory discounts and strong incentives to drive down costs. Swipe through to understand the specific discount ranges and how the patient co-payment mechanism works to steer choices toward more affordable alternatives. Essential reading for anyone involved in Swiss pharmaceutical strategy!
Swiss P&R: What is Your Legal Price Comparator?
For an innovative drug, your negotiation strategy isn't built on clinical data alone—it's built on a complex legal definition of 'The Comparator.' A recent Federal Administrative Court ruling overturned a massive 37.8% price cut because the FOPH selected the wrong legal benchmark. If your drug is an Orphan or a Niche asset, knowing which comparator to accept (and which to fight) is the difference between premium pricing and a mandated cut. This carousel breaks down the mandatory two-pillar pricing system and reveals the single greatest protection in your P&R dossier. Partner with a consultant who knows the legal lines. DM me to discuss your strategy."
Cracking the Code: Croatia's Strategic Role in EU Pharma Launch
The new EU Pharma Package poses a "2 Billion Question": Are you using Croatia to unlock your EU exclusivity? This carousel, drawn from a recent client project, reveals how rapid, successful entry in Zagreb — from HALMED approval to HZZO pricing — is your critical leverage point for securing EU-wide advantages and potentially billions in revenue. Don't let market fragmentation cost your valuable exclusivity.
Switzerland's Strategic Edge: A Clear Path to P&R for Your ATMP
Imagine a therapy that promises a one-time cure, but comes with an unprecedented price tag and evolving evidence. This is the reality of ATMPs. Switzerland has developed a highly specialized approach to bring these life-changing innovations to patients. Swipe through to discover the Swiss strategy for ATMP market access, from early dialogue to outcome-based agreements.
Navigating Different Regulatory Pathways For Your Health Product
The same product can be a cosmetic in one country and a drug in another. It all comes down to a product's intended use and the claims you make. This is the difference between a fast-to-market cosmetic and a years-long drug approval process. To win in today's market, you can't separate your regulatory strategy from your commercial goals.
The Pharma Pricing Shift: Why You Should Consider Switzerland as Your New First Launch Hub
The U.S. drug pricing landscape is changing. This shift presents new challenges, but also a significant opportunity for pharma companies to strategically rethink their global launch sequence.
Sur Access explores why Switzerland should be a key part of that conversation. Take a look to see how our team can help you navigate this evolving market.
Early Access to Medicines in Switzerland
Navigate the complex landscape of early drug access in Switzerland, from paid reimbursement pathways to unpaid regulatory programs, to unlock life-saving therapies for patients in need.
Unpacking Drug Pricing & Reimbursement in Switzerland
Unlock Swiss Market Potential: A Guide to Drug Pricing & Reimbursement
Switzerland: a leading market for pharmaceutical innovation, renowned for its high-quality healthcare and patient-centric approach. But navigating its unique regulatory and reimbursement landscape is key to sustainable success. This carousel breaks down how to thrive.
Defining Target Product Profile (TPP) for Early-Stage Biotech Companies
For early-stage biotech companies, establishing a robust TPP is not just a regulatory or technical exercise-it is fundamental to aligning innovation with patient needs, regulatory expectations, and market realities, at the earliest stage of drug development.
